Difference between revisions of "Postema EJ, et al. J. Nucl. Med. (2003) cited as Ref 553 in DOI: 10.1038/s41392-020-0110-5 (Q9816)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: PubMed ID (P140): 14530488, #quickstatements; #temporary_batch_1590001671040)
(‎Created claim: Page(s) (P105): 1690-1699, #quickstatements; #temporary_batch_1590074839150)
 
(4 intermediate revisions by the same user not shown)
Property / Publication Date
 +
2003
Timestamp+2003-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2003 / rank
 +
Normal rank
Property / Published In Name String
 +
J. Nucl. Med.
Property / Published In Name String: J. Nucl. Med. / rank
 +
Normal rank
Property / Volume
 +
44
Property / Volume: 44 / rank
 +
Normal rank
Property / title
 +
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer (English)
Property / title: Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer (English) / rank
 +
Normal rank
Property / Page(s)
 +
1690-1699
Property / Page(s): 1690-1699 / rank
 +
Normal rank

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Postema EJ, et al. J. Nucl. Med. (2003) cited as Ref 553 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Postema EJ
    0 references
    0 references
    2003
    0 references
    J. Nucl. Med.
    0 references
    44
    0 references
    Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer (English)
    0 references
    1690-1699
    0 references